<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795925</url>
  </required_header>
  <id_info>
    <org_study_id>APOGEPHA-8403030</org_study_id>
    <nct_id>NCT00795925</nct_id>
  </id_info>
  <brief_title>Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder</brief_title>
  <official_title>Dose-Escalating Study of Propiverine Hydrochloride (Mictonetten®) in Children Suffering From Frequency-Urgency-Syndrome and Urinary Incontinence Indicative of Detrusor Overactivity (Overactive Bladder)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>APOGEPHA Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>APOGEPHA Arzneimittel GmbH</source>
  <brief_summary>
    <textblock>
      The open-label dose-escalating two-centre study was designed to assess the pharmacokinetics
      as well as safety, tolerability and efficacy parameters of propiverine in patients 5-10 years
      of age suffering from frequency-urgency-syndrome and urinary incontinence indicative of
      detrusor overactivity (overactive bladder) for determination of the recommended dose in
      children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of propiverine and its main metabolite propiverine N-oxide at steady state: Ctrough, Cmax, Tmax, AUC0-8h. Children were separated into 3 groups.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of propiverine. Efficacy: Changes from baseline: voiding frequency, incontinence and urgency episodes,voided volume. Safety: Post Void Residual (PVR),adverse events,laboratory values (urine, blood), ECG.</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>propiverine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propiverine hydrochloride</intervention_name>
    <description>coated tablets containing 5 mg
consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d.</description>
    <arm_group_label>propiverine hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Micturition Frequency ≥6 micturitions during awake period

          -  Urge Incontinence Episodes ≥1/week

          -  Urgency Episodes ≥1/day

        Main Exclusion Criteria:

          -  Contraindication to anticholinergic therapy

          -  Repeated measurement of Post Void Residual ≥20 mL

          -  Nocturnal Enuresis

          -  Clinically significant cardiovascular, hepatic, renal, gastrointestinal or
             hematological disease, psychiatric disorder or diabetes insipidus

          -  Anatomical abnormalities of the urinary tract
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Ulla Sillen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drottning Silvias ,Barn- och ungdomssjukhus, SU/Östra,416 85 Göteborg</affiliation>
  </overall_official>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>November 20, 2008</last_update_submitted>
  <last_update_submitted_qc>November 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2008</last_update_posted>
  <keyword>propiverine</keyword>
  <keyword>anticholinergics</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>children</keyword>
  <keyword>dose-finding in children aged 5-10 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

